UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
Saint-Laurent, Quebec
H4S 2A1
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
May 21, 2004
By: /s/ David Skinner
----------------------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
[NEUROCHEM LOGO] NEUROCHEM INC.
275 Armand-Frappier Blvd
Laval, Quebec, Canada H7V 4A7
NEUROCHEM TO PRESENT AT
BANC OF AMERICA SECURITIES' HEALTH CARE CONFERENCE AND
AT UBS 2004 GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE
MONTREAL, CANADA, MAY 20, 2004 - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Friday, May 21, 2004, Dr. Francesco Bellini, Chairman
and CEO, will present Neurochem's overall strategy and progress to date at the
Banc of America Securities' Health Care Conference to be held in Las Vegas,
Nevada. The presentation will take place at 12:00 noon (PT). The corporate
presentation will be available on the Company's website at
http://www.neurochem.com/Investor.htm#Presentation.
An audio webcast of Neurochem's presentation can also be accessed at
http://www.veracast.com/webcasts/bas/healthcare-2004/id65307697.cfm.
This webcast will be available through to June 4, 2004.
Dr. Bellini will also present at the UBS 2004 Global Specialty Pharmaceuticals
Conference in New York City on May 24, 2004, at 3:30 P.M. (EDT). This
presentation will be available on the Company's website at
http://www.neurochem.com/Investor.htm#Presentation.
A webcast of this presentation can be accessed at: www.ibb.ubs.com and will be
available through to June 25, 2004.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs.
Fibrillex(TM), designated an orphan drug and a Fast Track Product candidate, is
in a Phase II/III clinical trial for AA Amyloidosis. Alzhemed(TM) and
Cerebril(TM), for the treatment of Alzheimer's Disease and for the prevention of
Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, respectively, have
both completed a Phase II clinical trial. For additional information on
Neurochem, please visit our website at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release. These statements speak only as of the date made and Neurochem
is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
Tel: (450) 680-4570
Fax: (450) 680-4501
- 2 -